<DOC>
	<DOC>NCT02186223</DOC>
	<brief_summary>The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel速 Catheter in subjects at high risk of PE, and with recognized contraindications to standard pharmacological therapy (anticoagulation).</brief_summary>
	<brief_title>The Angel速 Catheter Pivotal Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<criteria>1. Subject or legally authorized representative is willing and able to provide written informed consent, 2. Subject is 18 years or older, 3. Subject is expected to remain in a critical care setting for at least 72 hours, AND at least one of the following inclusion criteria (4,5, and/or 6) 4. Subject has recognized contraindications to standard pharmacological thromboprophylaxis including: Active bleeding or at high risk for bleeding OR Hypersensitivity to pharmacological thromboprophylaxis OR History of severe heparin induced thrombocytopenia OR Severe thrombocytopenia 5. Subject has a confirmed acute proximal lower extremities DVT or a confirmed acute PE with recognized contraindication to anticoagulation 6. Subject requires a temporary interruption (&gt;24 hours) of pharmacological thromboprophylaxis for a surgical or medical procedure 1. Subject is pregnant 2. Subject is in treatment with an investigational drug or device within 30 days prior to enrollment 3. Subject has a preexisting IVC filter in place 4. BMI = &gt; 45 5. Subject has functioning pelvic renal allograft on the only side available for device insertion 6. Subject has undergone a surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted 7. Anatomic inability to place the Angel速 Catheter 8. Subject has known hypersensitivity to any of the components of the Angel速 Catheter, specifically Nitinol (nickel and/or titanium)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>PE</keyword>
	<keyword>DVT</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>VTE</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>thromboprophylaxis</keyword>
	<keyword>contraindications to thromboprophylaxis</keyword>
	<keyword>prophylactic</keyword>
	<keyword>prevention</keyword>
	<keyword>Inferior vena cava filter</keyword>
	<keyword>IVC filter</keyword>
	<keyword>filter</keyword>
	<keyword>prevention of pulmonary embolism</keyword>
	<keyword>trauma</keyword>
	<keyword>critically-ill</keyword>
</DOC>